Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents-Reference-Cited by-同舟云学术

Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents

Published:2013-03-08 Issue:5 Volume:54 Page:1117-1119
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ronchetti Anne-Marie,Isnard Françoise,Buffet Marc,Coman Tereza,Gorin Norbert-Claude,Coppo Paul,Garderet Laurent,Malak Sandra

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.733879

Reference10 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Treatment Options for Relapsed and Refractory Multiple Myeloma

3. Genomic stratification of multiple myeloma treated with novel agents

4. Treatment of relapsed and refractory myeloma

5. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of multiple myeloma: A monoclonal plasma cell malignancy’s diagnosis, management, and treatment modalities;Saudi Journal of Biological Sciences;2024-02

2. Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies;Current Oncology;2022-06-23

3. Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease;Leukemia & Lymphoma;2021-04-01

4. DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation;British Journal of Haematology;2020-11-25

5. Leptotrichia Bacteremia After Chemotherapy for Hematologic Malignancy;American Journal of Therapeutics;2019-11